Induction Immunosuppression With Basiliximab in Heart Transplantation

Transplantation Proceedings

Volumn 40, Issue 8, 2008, Pages 2623-2625

  Chou, N K ^a   Wang, S S ^a   Chen, Y S ^a   Yu, H Y ^a   Chi, N H ^a   Wang, C H ^a   Ko, W J ^a   Tsao, C I ^a   Sun, C D ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CYCLOSPORIN; EVEROLIMUS; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENTEROBACTER CLOACAE; FEMALE; GRAFT FAILURE; GRAFT REJECTION; HEART MUSCLE BIOPSY; HEART TRANSPLANTATION; HEMODYNAMICS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; POSTOPERATIVE CARE; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; SEPSIS; SURGICAL MORTALITY; SURGICAL TECHNIQUE; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; ANIMALS; ANTIBODIES, MONOCLONAL; ANTILYMPHOCYTE SERUM; CARDIOMYOPATHY, DILATED; ENTEROBACTER CLOACAE; ENTEROBACTERIACEAE INFECTIONS; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; POSTOPERATIVE COMPLICATIONS; RABBITS; RECOMBINANT FUSION PROTEINS; RETROSPECTIVE STUDIES; SEPSIS;

EID: 53149128006     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2008.07.113     Document Type: Article

References (9)

1. Kahan B.D., Rajagopalan P.R., and Hall M. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody: United States Simulect Renal Study Group. Transplantation 67 (1999) 276
2. Mehra M.R., Zucker M.J., Wagoner L., et al. A multicenter, prospective, randomized, double-blind trial of basiliximab in heart transplantation. J Heart Lung Transplant 24 (2005) 1297
3. Ford K.A., Cale C.M., Rees P.G., et al. Initial data on basiliximab in critically ill children undergoing heart transplantation. J Heart Lung Transplant 24 (2005) 1284
4. Delgado D.H., Miriuka S.G., Cusimano R.J., et al. Use of basiliximab and cyclosporine in heart transplant patients with pre-operative renal dysfunction. J Heart Lung Transplant 24 (2005) 166
5. Flaman F., Zieroth S., Rao V., et al. Basiliximab versus rabbit anti-thymocyte globulin for induction therapy in patients after heart transplantation. J Heart Lung Transplant 25 (2006) 1358
6. Rosenberg P.B., Vriesendorp A.E., Drazner M.H., et al. Induction therapy with basiliximab allows delayed initiation of Cyclosporine and preserves renal function after cardiac transplantation. J Heart Lung Transplant 24 (2005) 1327
7. Mattei M.F., Redonnet M., Gandjbakhch I., et al. Lower risk of infectious deaths in cardiac transplant patients receiving basiliximab versus anti-thymocyte globulin as induction therapy. J Heart Lung Transplant 26 (2007) 693
8. Segovia J., Rodriguez-Lambert J.L., Crespo-Leiro M.G., et al. A randomized multicenter comparison of basiliximab and muromonab (OKT3) in heart transplantation: SIMCOR study. Transplantation 81 (2006) 1542
9. Carrier M., Leblanc M.H., Perrault L.P., et al. Basiliximab and rabbit anti-thymocyte globulin for prophylaxis of acute rejection after heart transplantation: a non-inferiority trial. J Heart Lung Transplant 26 (2007) 258